US Stock MarketDetailed Quotes
PHIO Phio Pharmaceuticals
- 0.8000
- -0.0364-4.35%
Close May 8 16:00 ET
- 0.8032
- +0.0032+0.40%
Post 16:03 ET
3.67MMarket Cap-153P/E (TTM)
0.8600High0.7700Low154.31KVolume0.8280Open0.8364Pre Close127.35KTurnover3.38%Turnover RatioLossP/E (Static)4.59MShares6.850052wk High0.48P/B3.65MFloat Cap0.500052wk Low--Dividend TTM4.56MShs Float346.4999Historical High--Div YieldTTM10.76%Amplitude0.5000Historical Low0.8250Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Phio Pharmaceuticals Stock Forum
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.
Preclinical studies demonstrate:
The data, authored by Melissa Maxwell, Lind...
NEWS
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead c...
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a renowned player in the biotechnology industry, has made a landmark achievement by securing patents for its innovative compounds RXI-185 and RXI-231. This significant development, recognized by the United States Patent and Trademark Office (USPTO), opens up new possibilities in the realm of...
No comment yet